Cargando…
Complement activation in patients with COVID-19: A novel therapeutic target
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Academy of Allergy, Asthma & Immunology
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7224678/ https://www.ncbi.nlm.nih.gov/pubmed/32417135 http://dx.doi.org/10.1016/j.jaci.2020.05.006 |
_version_ | 1783533949377576960 |
---|---|
author | Cugno, Massimo Meroni, Pier Luigi Gualtierotti, Roberta Griffini, Samantha Grovetti, Elena Torri, Adriana Panigada, Mauro Aliberti, Stefano Blasi, Francesco Tedesco, Francesco Peyvandi, Flora |
author_facet | Cugno, Massimo Meroni, Pier Luigi Gualtierotti, Roberta Griffini, Samantha Grovetti, Elena Torri, Adriana Panigada, Mauro Aliberti, Stefano Blasi, Francesco Tedesco, Francesco Peyvandi, Flora |
author_sort | Cugno, Massimo |
collection | PubMed |
description | |
format | Online Article Text |
id | pubmed-7224678 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | American Academy of Allergy, Asthma & Immunology |
record_format | MEDLINE/PubMed |
spelling | pubmed-72246782020-05-15 Complement activation in patients with COVID-19: A novel therapeutic target Cugno, Massimo Meroni, Pier Luigi Gualtierotti, Roberta Griffini, Samantha Grovetti, Elena Torri, Adriana Panigada, Mauro Aliberti, Stefano Blasi, Francesco Tedesco, Francesco Peyvandi, Flora J Allergy Clin Immunol Letter to the Editor American Academy of Allergy, Asthma & Immunology 2020-07 2020-05-14 /pmc/articles/PMC7224678/ /pubmed/32417135 http://dx.doi.org/10.1016/j.jaci.2020.05.006 Text en © 2020 American Academy of Allergy, Asthma & Immunology. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Letter to the Editor Cugno, Massimo Meroni, Pier Luigi Gualtierotti, Roberta Griffini, Samantha Grovetti, Elena Torri, Adriana Panigada, Mauro Aliberti, Stefano Blasi, Francesco Tedesco, Francesco Peyvandi, Flora Complement activation in patients with COVID-19: A novel therapeutic target |
title | Complement activation in patients with COVID-19: A novel therapeutic target |
title_full | Complement activation in patients with COVID-19: A novel therapeutic target |
title_fullStr | Complement activation in patients with COVID-19: A novel therapeutic target |
title_full_unstemmed | Complement activation in patients with COVID-19: A novel therapeutic target |
title_short | Complement activation in patients with COVID-19: A novel therapeutic target |
title_sort | complement activation in patients with covid-19: a novel therapeutic target |
topic | Letter to the Editor |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7224678/ https://www.ncbi.nlm.nih.gov/pubmed/32417135 http://dx.doi.org/10.1016/j.jaci.2020.05.006 |
work_keys_str_mv | AT cugnomassimo complementactivationinpatientswithcovid19anoveltherapeutictarget AT meronipierluigi complementactivationinpatientswithcovid19anoveltherapeutictarget AT gualtierottiroberta complementactivationinpatientswithcovid19anoveltherapeutictarget AT griffinisamantha complementactivationinpatientswithcovid19anoveltherapeutictarget AT grovettielena complementactivationinpatientswithcovid19anoveltherapeutictarget AT torriadriana complementactivationinpatientswithcovid19anoveltherapeutictarget AT panigadamauro complementactivationinpatientswithcovid19anoveltherapeutictarget AT alibertistefano complementactivationinpatientswithcovid19anoveltherapeutictarget AT blasifrancesco complementactivationinpatientswithcovid19anoveltherapeutictarget AT tedescofrancesco complementactivationinpatientswithcovid19anoveltherapeutictarget AT peyvandiflora complementactivationinpatientswithcovid19anoveltherapeutictarget |